Arrowhead Pharmaceuticals, Inc. (ARWR) Down 5.2% — Is It Time to Unload?
Arrowhead Pharmaceuticals, Inc. (ARWR) was under pressure in today's session, last trading at $76.46 on the NASDAQ after shedding $4.21 from the prior close of $80.67. The move deepens the stock's retreat from its 52-week high of $95.49, reached on July 22, 2026 — shares are now trading roughly 19.9% below that peak, with today's session adding to the distance from that level. The 52-week range of $28.12 to $95.49 underscores just how volatile this name has been, and today's action keeps it trending in the wrong direction.
Volume has been notably subdued, with approximately 652,608 shares changing hands against a 90-day average of roughly 1.92 million. That represents a fraction of typical daily turnover — less than a third of the average — suggesting the selling pressure today is coming from a relatively thin subset of participants rather than a broad-based rush to the exits.
Why Arrowhead Pharmaceuticals, Inc. Price is Moving Lower
Today's decline looks like a classic sell-the-news reaction, with the market discounting what were, on their face, genuinely encouraging clinical results. Arrowhead reported preliminary single-dose Phase 1/2a data for ARO-DIMER-PA, its dual-functional RNAi molecule targeting mixed hyperlipidemia, and the numbers were striking: maximum reductions of 72% in PCSK9, 88% in APOC3, 54% in LDL cholesterol, 73% in triglycerides, 61% in non-HDL cholesterol, and 50% in ApoB. Those are the kinds of efficacy signals that would ordinarily generate significant enthusiasm in the cardiovascular RNAi space. The problem is that biotech stocks frequently rally into data readouts, pricing in optimism in advance — and when the data lands, even strong results can trigger profit-taking as traders who bought the rumor exit their positions.
The disconnect between positive clinical news and a 5.22% decline is a familiar pattern for clinical-stage names with elevated valuations and no earnings to anchor the stock. With a negative EPS of -$2.25 and a forward P/E of -35.92, Arrowhead remains firmly in the pre-profitability camp, and any softness in sentiment — however irrational in the face of strong efficacy data — tends to be amplified. Investors holding a D- rated stock with a negative profit margin of -47.78% have limited fundamental cushion to fall back on when momentum reverses, and today's session reflects exactly that dynamic.
What is the Arrowhead Pharmaceuticals, Inc. Rating - Should I Sell?
Weiss Ratings assigns ARWR a D- rating. The rating was downgraded on 5/11/2026. Current recommendation is Sell.
The headline numbers tell a complicated story. Revenue growth of 171.02% is an eye-catching figure, reflecting meaningful progress in Arrowhead's collaboration and licensing revenue — deals with partners including GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics have contributed to sequential quarterly gains, with the latest quarter ending June 30, 2026 posting $75.25 million in revenue against $73.74 million the prior quarter. But that top-line momentum earns only a Weak Growth Index rating, a signal that Weiss's methodology is accounting for the irregularity and dependence on partnership milestones rather than durable commercial revenue. A profit margin of -47.78% earns a Very Weak Efficiency Index — a stark reminder that Arrowhead is consuming significant cash to advance a broad pipeline of RNAi candidates, with no near-term path to operating profitability in sight.
On the balance sheet, the picture brightens somewhat. The Good Solvency Index reflects a degree of financial stability sufficient to support continued pipeline investment — a meaningful attribute for a clinical-stage company that must fund multiple concurrent Phase 1/2a and Phase 3 programs. The Excellent Total Return Index acknowledges the stock's powerful multi-year run, including its ascent from a 52-week low of $28.12. However, the Weak Volatility Index is a candid assessment of the risk profile: ARWR swings sharply on clinical news, and today's session is a fresh example of how quickly sentiment can reverse even when the science is working.
Within the Health Care sector, Arrowhead sits at the bottom of a struggling peer group. Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), Revolution Medicines, Inc. (RVMD, D-), and BeOne Medicines AG (ONC, D-) all carry the same rating, while Chugai Pharmaceutical Co., Ltd. (CHGCF, D+) earns a slight edge. That relative standing reinforces the Sell recommendation — ARWR is not distinguishing itself on a risk-adjusted basis within an already challenged corner of the Health Care universe.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a Health Care company founded in 2003 and headquartered in Pasadena, California. The company is focused on developing RNA interference therapies for serious diseases, leveraging its proprietary RNAi technology platform to silence disease-causing genes at the hepatic level. Its approach is built around precision targeting — the goal being to reduce or eliminate the production of specific proteins implicated in cardiovascular, metabolic, and other intractable conditions.
The pipeline reflects an ambitious breadth of clinical activity. Most advanced are Plozasiran, targeting apolipoprotein C-III in Phase 3 studies for severe hypertriglyceridemia, and Zodasiran, targeting angiopoietin-like protein 3 in Phase 3 trials — both programs with significant commercial potential if they reach approval. Earlier-stage candidates include ARO-DIMER-PA for mixed hyperlipidemia, ARO-PNPLA3 for liver disease, ARO-INHBE and ARO-ALK7 targeting metabolic pathways, ARO-RAGE for inflammatory conditions, and ARO-MAPT for neurological indications, as well as ARO-C3 and ARO-CFB in complement biology.
Arrowhead's commercial strategy leans heavily on collaboration and licensing partnerships, with agreements in place with GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc., and Sarepta Therapeutics, Inc. These arrangements provide milestone payments and co-development funding that support the company's research-intensive operating model. The depth of the pipeline across multiple therapeutic areas is a core competitive asset, though it also means the company carries substantial clinical execution risk across a large number of simultaneous programs.
Investor Outlook
Arrowhead Pharmaceuticals, Inc. (ARWR) carries a Weiss Rating of D- (Sell), and today's sell-the-news decline following strong ARO-DIMER-PA efficacy data is a reminder that positive science does not automatically translate into positive price action for pre-profitability biotechs trading below their 52-week highs. Investors will want to watch for Phase 3 readouts from Plozasiran and Zodasiran as the next meaningful catalysts, while monitoring whether the company's cash position and partnership revenue can sustain its broad pipeline through continued operating losses. See full rankings of all D--rated Health Care stocks inside the Weiss Stock Screener.
--